AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Genmab and AbbVie said their combination treatment reduced the risk of disease progression or death among patients newly diagnosed with a type of lymphoma in a late-stage study. The companies did not provide effect size or other numerical results in the report.